

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jay Lal MEHTA)	Confirmation No.: Unknown
)	
Application No.: 10/573,353)	Group Art Unit: 1751
)	
Filed: March 24, 2006)	Examiner: Unknown
)	
For: THERAPEUTIC TREATMENT)	
)	Date: June 8, 2007

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant requests the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicant does not believe a fee is due for filing this Information Disclosure Statement.

With the exception of U.S. Patents and Publications, copies of the listed documents are attached. Applicant respectfully requests that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


Applicant also wishes to call to the Examiner's attention copending US Appln. 10/935,747 of Applicant's assignee having technically related subject matter, currently pending before Examiner Nancy L. Zhang in Art Unit 1614, in which Applicant responded to a non-final rejection on April 4, 2007. US

Appln. 10/935,747 is a continuation of prior Appln. No. 09/889,409, which issued as US Patent 6,894,058 on May 17, 2005.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicant reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: June 8, 2007
Morgan Lewis & Bockius LLP
Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:

Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. 056291-5246		Application No. 10/573,353	
				Applicants: Jay Lal MEHTA			
				Filing Date: March 24, 2006		Group Art Unit: Unassigned	
PTO Form 1449 June 8, 2007							
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
	1.	US 5,196,444	March 23, 1993	Naka et al.	514	381	April 18, 1991
	2.	US 5,298,497	March 29, 1994	Tschollar, et al.	514	91	June 1, 1992
	3.	US 5,328,919	July 12, 1994	Naka et al.	514	381	January 5, 1993
	4.	US 5,401,764	March 28, 1995	Naka et al.	514	381	May 10, 1993
	5.	US 5,703,110	December 30, 1997	Naka et al.	514	396	September 17, 1996
	6.	US 5,705,517	January 6, 1998	Naka et al.	514	381	October 5, 1993
	7.	US 5,721,263	February 24, 1998	Inada et al.	514	381	December 7, 1994
	8.	US 5,958,961	September 28, 1999	Inada et al.	514	394	June 26, 1997
	9.	US 5,962,491	October 5, 1999	Naka et al.	514	381	September 8, 1997
	10.	US 6,004,989	December 21, 1999	Naka et al.	514	381	March 29, 1999
	11.	US 6,228,874	May 8, 2001	Inada et al.	514	364	May 4, 2000
	12.	US 6,232,334	May 15, 2001	Naka et al.	514	381	August 18, 1999
	13.	US 6,348,481	February 19, 2002	Inada et al.	514	364	January 12, 2001
	14.	US 6,355,808	March 12, 2002	Naka et al.	548	252	March 27, 2001
	15.	US 6,420,405	July 16, 2002	Inada et al.	514	381	February 15, 2001
	16.	US 6,894,058	May 17, 2005	Cameron, et al	514	275	February 22, 2002
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
	17.	EP 0 457 514	November 21, 1991	EPO			
	18.	EP 0 521 471	January 7, 1993	EPO			
	19.	EP 0 628 313	December 14, 1994	EPO			
	20.	EP 0 753 301	January 15, 1997	EPO			
	21.	EP 1 306 088	May 2, 2003	EPO			
	22.	EP 1 306 089	May 2, 2003	EPO			
	23.	EP 1 314 425	May 28, 2003	EPO			
	24.	GB 2361 185	October 17, 2001	Great Britain			
	25.	GB 2361 186	October 17, 2001	Great Britain			
	26.	JP 10-81633	March 31, 1998	Japan			Abstract
	27.	JP 2002-145770	May 22, 2002	Japan			Abstract
	28.	WO 93/08823	May 13, 1993	WIPO			
	29.	WO 95/26188	October 5, 1995	WIPO			
	30.	WO 97/19917	June 5, 1997	WIPO			Abstract
	31.	WO 97/37688	October 16, 1997	WIPO			
	32.	WO 99/11260	March 11, 1999	WIPO			
	33.	WO 99/11263	March 11, 1999	WIPO			
	34.	WO 00/42024	July 20, 2000	WIPO			
	35.	WO 00/45817	August 10, 2000	WIPO			
	36.	WO 00/45818	August 10, 2000	WIPO			
	37.	WO 00/45819	August 10, 2000	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 June 8, 2007				Attorney Docket No. 056291-5246		Application No. 10/573,353	
				Applicants: Jay Lal MEHTA			
				Filing Date: March 24, 2006		Group Art Unit: Unassigned	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
	38.	WO 00/49014	August 24, 2000	WIPO			
	39.	WO 00/50007	August 31, 2000	WIPO			
	40.	WO 01/15674	March 8, 2001	WIPO			
	41.	WO 01/15744	March 8, 2001	WIPO			
	42.	WO 01/28555	April 26, 2001	WIPO			
	43.	WO 01/37808	May 31, 2001	WIPO			
	44.	WO 01/54669	August 2, 2001	WIPO			
	45.	WO 01/60804	August 23, 2001	WIPO			
	46.	WO 01/72706	October 4, 2001	WIPO			
	47.	WO 01/74394	October 11, 2001	WIPO			
	48.	WO 01/76573	October 18, 2001	WIPO			
	49.	WO 02/41895	May 30, 2002	WIPO			
	50.	WO 03/032995	April 24, 2003	WIPO			
	51.	WO 2004/096810	November 11, 2004	WIPO			
	52.	WO 2004/108691	December 16, 2004	WIPO			
	53.	WO 2005/023779	March 17, 2005	WIPO			
	54.	WO 2005/028450	March 31, 2005	WIPO			
	55.	WO 2005/030215	April 7, 2005	WIPO			
	56.	WO 2005/039638	May 6, 2005	WIPO			
	57.	WO 2005/042522	May 12, 2005	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	58.	Beaudeau et al. "The Potential Role of Matrix Metalloproteinases in the Treatment of Atherosclerosis" Annales de Biologie Clinique 61: 147-158 (2003)					
	59.	Bellosa et al. "HMG-CoA Reductase Inhibitors Reduce MMP-9 Secretion by Macrophages" Arteriosclerosis, Thrombosis, and Vascular Biology 18: 1671-1678 (1998)					
	60.	Bocan et al. "The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits" Arteriosclerosis, Thrombosis, and Vascular Biology 20: 70-79 (2000)					
	61.	Bocan, T. "Pleiotropic Effects of HMG-CoA Reductase Inhibitors" Current Opinion in Investigational Drugs 3(9): 1312-1317 (2002)					
	62.	Borghi, C. "Interactions Between Hypercholesterolemia and Hypertension: Implications for Therapy" Current Opinion in Nephrology and Hypertension 11: 489-496 (2002)					
	63.	Borghi et al. "Use of Lipid-Lowering Drugs and Blood Pressure Control in Patients with Arterial Hypertension" The Journal of Clinical Hypertension 4 (4): 277-285 2002					
	64.	Brizzi et al. "Interleukin-3 Stimulates Migration and Proliferation of Vascular Smooth Muscle Cells: A Potential Role in Atherogenesis" Circulation 103: 549-554 (2001)					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 June 8, 2007				Attorney Docket No. 056291-5246		Application No. 10/573,353	
				Applicants: Jay Lal MEHTA			
				Filing Date: March 24, 2006		Group Art Unit: <i>Unassigned</i>	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	65.	Chen et al. "Attenuation of Tissue P-Selectin and MCP-1 Expression and Intimal Proliferation by AT Receptor Blockade in Hyperlipidemic Rabbits" Biochemical and Biophysical Research Communications 282:474-479 (2001)					
	66.	Chen et al. "Cross-Talk Between Dyslipidemia and Renin-angiotensin System and the Role of LOX-1 and MAPK in Atherogenesis Studies With The Combined Use of Rosuvastatin and Candesartan" Atherosclerosis 184 295-301 (2006)					
	67.	Chen et al. "Direct Effects of Statins on Cells Primarily Involved in Atherosclerosis" Hypertension Research 23: 187-192 (2000)					
	68.	Chen et al. "Inhibitory Effect of Candesartan and Rosuvastatin on CD40 and MMPs Expression in Apo-E Knockout Mice" J Cardiovasc Pharmacol 44 (4): 446-452 (2004)					
	69.	Chen et al. "Interaction of Oxidized Low-density Lipoprotein and the Renin-Angiotensin System in Coronary Artery Disease" Current Hypertension Reports 8: 139-143 (2006)					
	70.	Chen et al. "Marked Upregulation of Lipoxigenase-1, a Receptro for Ox-Low-Density Lipoprotein in Atherosclerosis, and Its Total Ablation by Candesartan and Rosuvastatin Given Concurrently" Journal of the American College of Cardiology 1122-166 498A (2004)					
	71.	Chen et al. "Modulation of Matrix Metalloproteinase-1, Its Tissue Inhibitor, and Nuclear Factor-kB by Losartan in Hypercholesterolemic Rabbits" Journal of Cardiovascular Pharmacology 39: 332-339 (2002)					
	72.	Chen et al. "Preservation of Endogenous Antioxidant Activity and Inhibition of Lipid Peroxidation as Common Mechanisms of Antiatherosclerotic Effects of Vitamin E, Lovastatin and Amlodipine" Journal of the American College of Cardiology 30: 569-575 (1997)					
	73.	Chen et al. "Upregulation of LOX-1 Expression in Aorta of Hypercholesterolemic Rabbits: Modulation by Losartan" Biochemical and Biophysical Research Communications 276: 1100-1104 (2000)					
	74.	Chiariello, et al. "A Biochemical Method for the Quantitation of Myocardial Scfarring after Experimental Coronary Artery Occlusion" J Mol Coll Cardiol 18: 283-290 (1986)					
	75.	Chobanian et al. "Influence of Hypertension on Aortic Atherosclerosis in the Wantanabe Rabbit" Hypertension 14: 203-209 (1989)					
	76.	Crisby et al. "Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization" Circulation 103: 926-933 (2001)					
	77.	Cyrus et al. "Lipid Peroxidation and Platelet Activation in Murine Atherosclerosis" Circulation 104: 1940-1945 (2001)					
	78.	J.E. Deanfield "Targeting the Atherosclerotic Process in Clinical Practice. A New Look at Established Agents" Atherosclerosis 165 189-190 (2002)					
	79.	Faggiotto et al. "Statins and Blockers of the Renin-Angiotensin System Vascular Protection Beyond Their Primary Mode of Action" Hypertension 34 (part 2): 987-996 (1999)					
	80.	Faia et al. "Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Hamster Aortic Atherosclerosis: Correlation with In-Situ Zymography" Atherosclerosis 160: 325-337 (2002)					
	81.	Ferrario et al. "The Hypertension-Lipid Connection: Insights Into the Relation Between Angiotensin II and Cholesterol in Atherogenesis" American Journal of the Medical Sciences 323 (1): 17-24 (2002)					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 June 8, 2007				Attorney Docket No. 056291-5246		Application No. 10/573,353	
				Applicants: Jay Lal MEHTA			
				Filing Date: March 24, 2006		Group Art Unit: Unassigned	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	82.	Funakoshi et al. "Rho-Kinase Mediates Angiotensin II-Induces Monocyte Chemoattractant Protein-1 Expression in Rat Vascular Smooth Muscle Cells" Hypertension 38 100-104 (2001)					
	83.	Gaddam et al. "Anti-thrombotic Effects of Atorvastatin – An Effect Unrelated to Lipid Lowering" J Cardiovasc Pharmacol Therapeut 7 (4): 247-253 (2002)					
	84.	Gennaro et al. "Role of p44/p42 MAP Kinase in the Age-Dependent Increase in Vascular Smooth Muscel Cell Proliferation and Neointimal Formation" Arteriosclerosis, Thrombosis, and Vascular Biology" 23: 204-210 (2003)					
	85.	Goetze et al. "TNF Induces Expression of Transcription Factors c-fos, Egr-1, and Ets-1 in Vascular Lesions Through Extracellular Signal-Regulated Kinases 1/2" Atherosclerosis 159: 93-101 (2001)					
	86.	Han et al. "Evidence for Apoptosis in Human Atherogenesis and in a Rat Vascular Injury Model" American Journal of Pathology 147: 267-277 (1995)					
	87.	Hayek et al. "The Engiotensin-Converting Enzyme Inhibitor, Fosinopril, and athe Angiotensin II Receptor Antagonist, Losartan, Inhibit LDL Oxidation and Attenuate Atherosclerosis Independent of Lowering Blood Pressure in Apolipoprotein E Deficient Mice" Cardiovascular Research 44: 579-587 (1999)					
	88.	Holman et al. "Technics for Studying Atherosclerotic Lesions" Laboratory Investigation 7 42-47 (1958)					
	89.	Horton et al. "Ligation of CD40 on Vascular Smooth Muscle Cells Mediates Loss of Interstitial Collagen via Matrix Metalloproteinase Activity" Annals of New York Academy of Sciences 947: 329-336 (2001)					
	90.	Hu et al. "Hyperexpression and Activation iof Extracellular Signal-Regulated Kinases (ERK1/2) in Atherosclerotic Lesion of Cholesterol-Fed Rabbits" Arteriosclerosis, Thrombosis, and Vascular Biology 20: 18-26 (2000)					
	91.	Ikeda et al. "Monocyte-Endothelial Cell Interaction in Atherogenesis and Thrombosis" Clin. Cardiol. 21 11-14 (1998)					
	92.	Ikeda et al. "Statins and Monocytes" The Lancet 353: 2070 (1999)					
	93.	Ito et al. "Novel Mechanism for Endothelial Dysfunction: Dysregulation of Dimethylarginine Dimethylaminohydrolase" Circulation 99: 3092-3095 (1999)					
	94.	Iwai-Kanai et al. "Activation of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Induces Apoptosis in Cultured Neonatal Rat Cardiac Myocytes" Circulation 104: 2948-2954 (2001)					
	95.	Jacobsson et al. "Antiatherosclerotic Effects of the Angiotensin-Converting Enzyme Inhibitors Captopril and Fosinopril in Hypercholesterolemic Minipigs" Journal of Cardiovascular Pharmacology 24: 670-677 (1994)					
	96.	Jacoby et al. "Renin-Angiotensin System and Atherothrombotic Disease" Arch Intern Med 163 1155-1164 (2003)					
	97.	Jing et al. "Activation of p38 Mitogen—Activated Protein Kinase by Oxidized LDL in Vascular Smooth Muscle Cells: Mediation via Pertussis Toxin-Sensitive G Proteins and Association With Oxidized LDL-Induced Cytotoxicity" Circulation Research 84: 831-839 (1999)					
	98.	Kaneko et al. Chemical Abstracts 118(11) (1993)					
	99.	Keidar et al. "Angiotensin II Injection into Mice Increases the Uptake of Oxidized LDL by Their Macrophages via a Proteoglycan-Mediated Pathway" Biochemical and Biophysical Research Communications 239: 63-67 (1997)					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 June 8, 2007		Attorney Docket No. 056291-5246		Application No. 10/573,353			
		Applicants: Jay Lal MEHTA					
		Filing Date: March 24, 2006		Group Art Unit: <i>Unassigned</i>			
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	100.	Keidar et al. "Angiotensin II Stimulates Macrophage-Mediated Oxidation of Low Density Lipoproteins" Atherosclerosis 115: 201-215 (1995)					
	101.	Knox et al. "Evidence for Altered Balance between Matrix Metalloproteinases and Their Inhibitors in Human Aortic Diseases" Circulation 95: 205-212 (1997)					
	102.	Lacoste et al. "Hyperlipidemia and Coronary Disease" Circulation 92 (31) 3172-3177 (1995)					
	103.	Li et al. "Angiotensin II via Activation of Type 1 Receptor Upregulates Expression of Endoglin in Human Coronary Artery Endothelial Cells" Hypertension 38: 1062-1067 (2001)					
	104.	Li et al. "LOX-1 Inhibition in Myocardial Ischemia-Reperfusion Injury: Modulation of MMP-1 and Inflammation" Am J Physiol Heart Circ Physiol 283: H1795-H1801 (2002)					
	105.	Li et al. "LOX-1 Mediates Oxidized Low-Density Lipoprotein-Induced Expression of Matrix Metalloproteinases in Human Coronary Artery Endothelial Cells" Circulation 107: 612-617 (2003)					
	106.	Li et al. "Modulation of Constitutive Nitric Oxide Synthase, bcl-2 and Fas Expression in Cultured Human Coronary Endothelial Cells Exposed to Anoxia-Reoxygenation and Angiotensin II: Role of AT1 Receptor Activation" Cardiovascular Research 41: 109-115 (1999)					
	107.	Li et al. "Oxidized-LDL Through LOX-1 Increases the Expression of Angiotensin Converting Enzyme in Human Coronary Artery Endothelial Cells" Cardiovascular Research 57: 238-243 (2003)					
	108.	Li et al. "Oxidized LDL Upregulates Angiotensin II Type 1 Receptor Expression in Cultured Human Coronary Artery Endothelial Cells" Circulation 102: 1970-1976 (2000)					
	109.	Li et al. "Statins Inhibit Oxidized-LDL-Mediated LOX-1 Expression, Uptake of Oxidized-LDL and Reduction in PKB Phosphorylation" Cardiovascular Research 52: 130-135 (2001)					
	110.	Li et al. "Statins Modulate Oxidized Low-Density Lipoprotein-Mediated Adhesion Molecule Expression in Human Coronary Artery Endothelial Cells: Role of LOX-1" Journal of Pharmacology and Experimental Therapeutics 302: 601-605 (2002)					
	111.	Li et al. "Upregulation of Endothelial Receptor for Oxidized Low-Density Lipoprotein (LOX-1) in Cultured Human Coronary Artery Endothelial Cells by Angiotensin II Type 1 Receptor Activation" Circulation Research 84: 1043-1049 (1999)					
	112.	H. R. Lijnen "Non-Haemostatic Role for blood Coagulation Proteases and Their Receptors" Biochemical Society 163-167 (2002)					
	113.	Manning et al. "Differential Effects of Doxycycline, a Broad-Spectrum Matrix Metalloproteinase Inhibitor, on Angiotensin II-Induced Atherosclerosis and Abdominal Aortic Aneurysms" Arteriosclerosis, Thrombosis, and Vascular Biology 23: 483-488 (2003)					
Examiner			Date Considered				
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 June 8, 2007				Attorney Docket No. 056291-5246		Application No. 10/573,353	
				Applicants: Jay Lal MEHTA			
				Filing Date: March 24, 2006		Group Art Unit: <i>Unassigned</i>	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	114.	Menges et al. "Oxidative Degradation of γ -Butyrolactons into 1,3-Diols via a Criegee Rearrangement of Peroxosulfonates. An Enantioselective Synthesis of Capactin Lactone and its Diastereomer" Synlett 901-905 (1993)					
	115.	Mehta et al. "Angiotensin II and IV Stimulate Expression and Release of Plasminogen Activator Inhibitor-1 in Cultured Human Coronary Artery Endothelial Cells" Journal of Cardiovascular Pharmacology 39: 789-794 (2002)					
	116.	J.L. Mehta "Critical Role of Dyslipidemia and Angiotensin II in Atherogenesis. In: Molecular Mechanisms in Hypertension" R Re, D DiPette, E Schiffrin, J Sowers, Taylor & Francis, London (2006)					
	117.	M. H. Moghadasian "Clinical Pharmacology of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors" Life Sciences 65 (13): 1329-1337 (1999)					
	118.	Morikawa et al. "The Effect of Statins on mRNA Levels of Genes Related to Inflammation, Coagulation, and Vascular Constriction in HUVEC" Journal of Atherosclerosis and Thrombosis 9 (4): 178-183 (2002)					
	119.	Nahmod et al. "Control of Dendritic Cell Differentiation by Angiotensin II" FASEB Journal 17: 491-493 (2003)					
	120.	Noji et al. "Circulating Matrix Metalloproteinases and Their Inhibitors in Premature Coronary Atherosclerosis" Clin Chem Lab Med 39 (5): 380-384 (2001)					
	121.	Notarbartolo et al. "Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa Hypercholesterolemia" Arteriosclerosis, Thrombosis, and Vascular Biology 15: 247-251 (1995)					
	122.	Palinsky et al. "ApoE-Deficient Mice Are A Model of Lipoprotein Oxidation in Atherogenesis. Demonstration of Oxidation-Specific Epitopes in Lesions and High Titers of Autoantibodies to Malondialdehyde-Lysine in Serum" Arteriosclerosis, Thrombosis, and Vascular Biology 14: 605-616 (1994)					
	123.	R. P. Phipps "Atherosclerosis: The Emerging Role of Inflammation and the CD40-CD40 Ligand System" PNAS 97 (13): 6930-6932 (2000)					
	124.	Pullen et al. "CD40 Signaling Through Tumor Necrosis Factor Receptor-Associated Factors (TRAFs)" The Journal of Biological Chemistry 274 (20): 14246-14254 (1999)					
	125.	Ramos et al. "Direct Demonstration of P-Selectin- and VCAM-1-Dependent Mononuclear Cell Rolling in Early Atherosclerotic Lesions of Apolipoprotein E-Deficient Mice" Circulation Research 84: 1237-1244 (1999)					
	126.	Rosenson et al. "Statin Use In Acute Coronary Syndromes: Cellular Mechanisms and Clinical Evidence" Current Opinion Lipidol 13: 625-630 (2002)					
	127.	Rouis et al. "Adenovirus-Mediated Overexpression of Tissue Inhibitor of Metalloproteinase-1 reduces Atherosclerotic Lesions in Apolipoprotein E-Deficient Mice" Circulation 100: 533-540 (1999)					
	128.	Sakaki, et al. "Lipase-catalyzed Asymmetric Synthesis of 6-(3-Chloro-2-hydroxypropyl)-1,3-dioxin-4-ones and Their Conversion to Chiral 5,6-Epoxyhexanoates" Tetrahedron Asymmetry 2(5): 343-346 (1991)					
	129.	Schönbeck et al. "CD40 Signaling and Plaque Instability" Circulation Research 89: 1092-1103 (2001)					
	130.	Schönbeck et al. "Expression of Stromelysin-3 in Atherosclerotic Lesions: Regulation via CD40-CD40 Ligand Signaling In Vitro and In Vivo" J. Exp. Med. 189: (5) 843-853 (1999)					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) PTO Form 1449 June 8, 2007	Attorney Docket No. 056291-5246	Application No. 10/573,353
	Applicants: Jay Lal MEHTA	
	Filing Date: March 24, 2006	Group Art Unit: <i>Unassigned</i>

U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Sub-Class	Translation

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

131.	Schönbeck et al. "Inhibition of CD40 Signaling Limits Evolution of Established Atherosclerosis in Mice" PNAS 97 (13): 7458-7463 (2000)
132.	Schönbeck et al. "Oxidized Low-Density Lipoprotein Augments and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 and CD40L Expression in Human Vascular Cells" Circulation 106: 2888-2893 (2002)
133.	Semb et al. "Raised Serum Levels of Soluble CD40 Ligand in Patients With Familial Hypercholesterolemia: Downregulatory Effect of Statin Therapy" Journal of the American College of Cardiology 41 (2): 275-279 (2003)
134.	Shao et al. "Asymmetric Hydrogenation of 3,5-Dioxoesters Catalyzed by Ru-binap Complex: A Short Seep Asymmetric Synthesis of 6-Substituted 5,6-dihydro-2-pyrones" Tetrahedron 49(10): 1997-2010 (1993)
135.	Singh et al. "Interactions Between the Renin-Angiotensin System and Dyslipidemia: Relevance in Atherogenesis and Therapy of Coronary Heart Disease" Indian Heart J 53: 511-518 (2001)
136.	Singh et al. "Interactions Between the Renin-Angiotensin System and Dyslipidemia" Arch Intern Med 163: 1296-1304 (2003)
137.	Strawn et al. "Inhibition of Early Atherogenesis by Losartan in Monkeys With Diet-Induced Hypercholesterolemia" Circulation 101: 1586-1593 (2000)
138.	Tamarat et al. "Angiotensin II Angiogenic Effect In Vivo Involves Vascular Endothelial Growth Factor- and Inflammation-Related Pathways" Laboratory Investigation 82 (6): 747-756 (2002)
139.	Tayeh et al. "Angiotensin II and Bradykinin Regulate the expression P-Selectin on the Surface of Endothelial Cells in Culture" Proceedings of the Association of American Physicians 110 (5): 412-421 (1998)
140.	Wantanabe, et al. "Antioxidant N-Acetylcysteine Inhibits Vasoactive Agents-Potentiated Mitogenic Effect of Mildly Oxidized LDL on Vascular Smooth Muscle Cells" Hypertension Research - Clinical & Experimental 25: 311-315 (2002)
141.	Wantanabe, et al. "Synthesis and Biological Activity of Methanesulfonamide Pyrimidine- and N-Methanesulfonyl Pyrrole-Substituted 3,5-Dihydroxy-6-Heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors" Bioorganic & Medicinal Chemistry 5 (2): 437-444 (1997)
142.	Werle, et al. "MCP-1 Induces Activation of MAP-Kinases ERK, JNK and p38 MAPK in Human Endothelial Cells" Cardiovascular Research 56: 284-292 (2002)
143.	Yang et al. "Increase in Angiotensin II Type 1 Receptor Expression Immediately After Ischemia-Reperfusion in Isolated Rat Hearts" Circulation 96: 922-926 (1997)
144.	Yang et al. "Increased Angiotensin II Type 1 Receptor Expression in Hypercholesterolemic Atherosclerosis in Rabbits" Atheroscler Thromb Vasc Biol 18: 1433-1439 (1998)

Examiner	Date Considered
----------	-----------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.